Harvard Bioscience (HBIO) Receivables (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Receivables data on file, last reported at $14.6 million in Q1 2026.

• On a quarterly basis, Receivables rose 8.11% year-over-year to $14.6 million in Q1 2026; TTM through Mar 2026 was $14.6 million, a 8.11% increase from a year earlier, with the FY2025 full-year figure at $16.0 million, up 7.92% from the prior year.
• Receivables for Q1 2026 stood at $14.6 million, down from $16.0 million in the prior quarter.
• Over the last five years, Receivables for HBIO reached as high as $20.3 million in Q1 2022 and fell as low as $11.9 million in Q2 2025.
• Historically, Receivables has averaged $15.2 million across 5 years, with a median of $15.0 million in 2022.
• Across the five-year window, Receivables climbed 18.74% in 2022 and retreated 26.13% in 2024, its largest moves.
• Year by year, Receivables stood at $16.7 million in 2022, then declined by 3.63% to $16.1 million in 2023, then fell by 7.66% to $14.9 million in 2024, then advanced by 7.92% to $16.0 million in 2025, then fell by 9.17% to $14.6 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $14.6 million in Q1 2026, $16.0 million in Q4 2025, and $12.1 million in Q3 2025.